Alipogene Tiparvovec
drugOn this page
Also known as Alipogen tiparvovecGlybera
Summary
Alipogene Tiparvovec (CHEMBL2108304) is an approved gene (ATC C10AX10); indicated across 2 conditions including cardiovascular disorder and familial lipoprotein lipase deficiency.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Gene
- ATC class: C10AX10
- Indications: 2 conditions
- Clinical trials: 3
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2108304 |
| Name | Alipogene Tiparvovec |
| Type | Gene |
| Max phase | 4 |
| ATC | C10AX10 |
Also known as: Alipogen tiparvovec, Alipogene tiparvovec, Glybera, ALIPOGENE TIPARVOVEC
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
2 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| cardiovascular disorder | 4 | MONDO:0004995 | EFO:0000319 |
| familial lipoprotein lipase deficiency | 4 | MONDO:0009387 | MONDO:0009387 |
Clinical trials
Total trials: 3.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2/PHASE3 | 2 |
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00891306 | PHASE2/PHASE3 | COMPLETED | Efficacy and Safety of Human Lipoprotein Lipase (LPL)[S447X] Expressed by an Adeno-Associated Viral Vector in LPL-deficient Subjects |
| NCT01109498 | PHASE2/PHASE3 | UNKNOWN | Safety and Efficacy in LPL-Deficient Subjects of AMT-011, an Adeno-Associated Viral Vector Expressing Human Lipoprotein Lipase [S447X] |
| NCT02904772 | PHASE2 | WITHDRAWN | Alipogene Tiparvovec for the Treatment of LPLD Patients |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).